Acorda Therapeutics Overview
- Year Founded
-
1995
- Status
-
Acquired/Merged
- Employees
-
277
- Latest Deal Type
-
M&A
- Financing Rounds
-
28
- Investments
-
7
Acorda Therapeutics General Information
Description
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis. The company's Net product revenue is derived from the sales of Ampyra and Inbrija.
Contact Information
Website
www.acorda.comCorporate Office
- 2 Blue Hill Plaza
- 3rd Floor, Pearl River
- Ardsley, NY 10965
- United States
Corporate Office
- 2 Blue Hill Plaza
- 3rd Floor, Pearl River
- Ardsley, NY 10965
- United States
Acorda Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Acorda Therapeutics Comparisons
Industry
Financing
Details
Acorda Therapeutics Competitors (47)
One of Acorda Therapeutics’s 47 competitors is Pfizer (Vienna), a Corporation company based in Vienna, Austria.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Pfizer (Vienna) | Corporation | Vienna, Austria | ||||
| Evonile Pharma | Private Equity-Backed | Mumbai, India | ||||
| Regeneron Pharmaceuticals | Formerly VC-backed | Tarrytown, NY | ||||
| Pfizer Pakistan | Corporation | Karachi, Pakistan | ||||
| IPI Legacy Liquidation | Formerly VC-backed | Seattle, WA |
Acorda Therapeutics Patents
Acorda Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2020223299-A1 | Methods and compositions for treating cns injury | Inactive | 30-Apr-2019 | ||
| CA-3059180-A1 | Sustained release compositions of 4-aminopyridine | Active | 06-Apr-2017 | ||
| CA-3059180-C | Sustained release compositions of 4-aminopyridine | Active | 06-Apr-2017 | ||
| CA-2999990-A1 | Sustained release compositions of 4-aminopyridine | Pending | 29-Sep-2015 | ||
| US-20180344649-A1 | Sustained release compositions of 4-aminopyridine | Inactive | 29-Sep-2015 | A61K9/2866 |
Acorda Therapeutics Signals
Acorda Therapeutics Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Acorda Therapeutics Investments & Acquisitions (7)
Acorda Therapeutics’s most recent deal was a Merger/Acquisition with Biotie Therapies for . The deal was made on 18-Apr-2016.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Biotie Therapies | 18-Apr-2016 | Merger/Acquisition | Drug Discovery | ||
| Civitas Therapeutics | 23-Oct-2014 | Merger/Acquisition | Drug Delivery | ||
| NeurogesX | 10-Jul-2013 | Merger/Acquisition | Pharmaceuticals | ||
| Qutenza | 09-Jul-2013 | Corporate Asset Purchase | Buildings and Property | ||
| Neuronex | 21-Dec-2012 | Merger/Acquisition | Pharmaceuticals |
Acorda Therapeutics Exits (1)
Acorda Therapeutics’s most recent exit was on 09-Jul-2013 from Qutenza. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Qutenza | 09-Jul-2013 | Completed |
|
Acorda Therapeutics FAQs
-
When was Acorda Therapeutics founded?
Acorda Therapeutics was founded in 1995.
-
Where is Acorda Therapeutics headquartered?
Acorda Therapeutics is headquartered in Ardsley, NY.
-
What is the size of Acorda Therapeutics?
Acorda Therapeutics has 277 total employees.
-
What industry is Acorda Therapeutics in?
Acorda Therapeutics’s primary industry is Pharmaceuticals.
-
Is Acorda Therapeutics a private or public company?
Acorda Therapeutics is a Private company.
-
What is the current valuation of Acorda Therapeutics?
The current valuation of Acorda Therapeutics is .
-
What is Acorda Therapeutics’s current revenue?
The current revenue for Acorda Therapeutics is .
-
How much funding has Acorda Therapeutics raised over time?
Acorda Therapeutics has raised $753M.
-
Who are Acorda Therapeutics’s investors?
BlackRock, Cross Atlantic Partners, EDBI, Easton Capital Investment Group, and Endpoint Late Stage Fund are 5 of 27 investors who have invested in Acorda Therapeutics.
-
Who are Acorda Therapeutics’s competitors?
Pfizer (Vienna), Evonile Pharma, Regeneron Pharmaceuticals, Pfizer Pakistan, and IPI Legacy Liquidation are some of the 47 competitors of Acorda Therapeutics.
-
When was Acorda Therapeutics acquired?
Acorda Therapeutics was acquired on 10-Jul-2024.
-
Who acquired Acorda Therapeutics?
Acorda Therapeutics was acquired by Merz Therapeutics (Germany).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process